




# PHARMACEUTICAL 2022

Acasti Pharma Inc.  
Rank 117 of 466





RealRate

# PHARMACEUTICAL 2022

Acasti Pharma Inc.  
Rank 117 of 466



The relative strengths and weaknesses of Acasti Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acasti Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Acasti Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 142% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	62,372
Cost of Goods Sold	76
Intangible Assets	0
Liabilities, Current	1,579
Liabilities, Non-Current	0
Other Assets	86
Other Compr. Net Income	0
Other Expenses	6,845
Other Liabilities	5,219
Other Net Income	-3,259
Other Revenues	196
Property and Equipment	0
Research and Development	4,173
Selling, General and Administrative Expense	5,521

Output Variable	Value in 1000 USD
Assets	62,458
Liabilities	6,798
Expenses	16,615
Revenues	196
Stockholders Equity	55,660
Net Income	-19,678
Comprehensive Net Income	-19,678
Economic Capital Ratio	220%